Thermo Fisher Scentific

Q2 FY2026 EarningsQ2 FY26 results exceeded consensus expectations on both top and bottom lines, with revenue of $11.99B beating the $11.70B estimate (+2.50%) and Adjusted EPS of $6.03 surpassing the $5.71 mean (+5.57%). Performance was driven by a strong recovery in the pharma and biotech markets and the successful integration of the Clario acquisition, which bolstered the Laboratory Products and Biopharma Services segment (+12% YoY). While GAAP gross margin of 40.70% missed the 41.51% consensus (-0.81pct) due to unfavorable business mix, very strong productivity improvements via the PPI Business System successfully expanded Adjusted Operating Margins to 22.8%.